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Mutations in calreticulin (CALR) were recently described
to be present in the majority of patients with a JAK2-
unmutated myeloproliferative neoplasm (MPN).1,2 This
discovery has had rapid clinical impact, and testing for
CALR has been embedded in national and international
diagnostic guidelines.3–5 However, a human MPN-derived cell
line harboring a CALR mutation has not been reported and the
mechanisms by which mutated-CALR results in an MPN remain
unclear.
To begin to investigate the pathogenetic consequences of
mutant CALR, we searched for patient-derived cell lines
harboring CALR mutations. None were identiﬁed by exome
sequencing of 1015 cell lines, including 37 derived from
hematopoietic neoplasms.1 We therefore looked for cell lines
derived from patients with leukemic transformation of a
preceding MPN. Given that CALR and JAK2 mutations are
almost completely mutually exclusive,1,2,6 we focused on four
such lines known to lack a JAK2 mutation (MONO-MAC-6,
MARIMO, GDM-1 and ELF-153), and also tested a further 52 other
predominantly myeloid cell lines (Supplementary Table 1).
Mutation screening was done by Sanger sequencing as
previously described,1 and details of other methods are in the
Supplementary Information.
The only cell line found to harbor a CALR mutation was
MARIMO, originally derived from a 68-year-old female with
AML-M2, and an antecedent history of ET.7 MARIMO is negative
for JAK2V617F and MPL exon 10 mutations (data not shown)
and carries a heterozygous 61-basepair (bp) deletion in CALR
exon 9 (c.1099_1159del; L367fs*43), which, like all other
reported CALR mutations, results in a +1- bp shift in the reading
frame and thus generates a novel C terminus (Figure 1a). In
patients, the commonest two CALR mutations, accounting for
85% of cases, are a 52-bp deletion (type 1; c.1099_1150del;
L367fs*46) and a 5-bp insertion (type 2; c.1154_1155_ins;
K385fs*47).8 Both the type 1 deletion and the MARIMO deletion
are immediately preceded by a nucleotide sequence identical
to that at the 3’ end of the deletion (Figure 1a). The 61-bp
MARIMO deletion is readily detected by fragment analysis and
represents a useful positive control for diagnostic clinical testing
(Figure 1b).
Allele-speciﬁc PCR demonstrated expression of the mutant CALR
allele (Figure 1c). Compared with other cell lines derived from
patients with JAK2V617F (HEL, UKE-1 and SET-2) or CML (K562)
total CALRmRNA levels were 10-fold higher in MARIMO (Figure 1d)
and total CALR protein levels were also increased albeit more
modestly (Figure 1e).
MARIMO cells expressed cell surface marker CD15 but not other
progenitor or lineage-afﬁliated markers (Supplementary Table 2).
The proliferation and cell cycle status of MARIMO was unremark-
able compared with other myeloid lines (Supplementary Figure 1).
We next analysed cellular calcium stores since CALR has an
important role in endoplasmic reticulum (ER) mediated calcium
homeostasis9 and mutant CALR protein lacks variable numbers
of calcium binding sites present in the wild-type C terminus.
No signiﬁcant differences in basal cytoplasmic calcium levels
were found amongst the six cell lines tested (Figure 2a).
Cell lines were then treated with 1 μM thapsigargin, which blocks
ER Ca2+-ATPase channels resulting in ER calcium depletion and
increased cytosolic calcium levels.10 MARIMO cells showed the
slowest rate of increase of cytoplasmic calcium levels upon
addition of thapsigargin (Figure 2b), consistent with the concept
that mutant CALR alters ER dependent calcium homeostasis.
The mutual exclusivity of JAK2 and CALR mutations
argues that they may share pathogenetic mechanisms and has
been used to suggest that CALR mutations may activate
JAK2/STAT5 signaling. This concept is supported by expression
proﬁling of patient-derived granulocytes11 together with a
report that expression of CALR in Ba/F3 cells confers
interleukin-3 independence and is accompanied by increased
STAT5 phosphorylation.2 However other studies have reported
distinct transcriptional signatures in JAK2V617F-mutated and
JAK2V617F-unmutated MPNs.12,13 Interpretation of these
apparently conﬂicting results is complicated by several issues
including limitations of overexpression systems, the uncertain
relevance of granulocytes to disease pathogenesis and
difﬁculties inherent to studies of signaling in primary
cells containing variable proportions of mutant cells. To
circumvent some of these issues, and to gain insight into the
consequences of CALR mutations, we explored the properties of
MARIMO cells.
The dependence of MARIMO cells on JAK signaling
was initially assessed using the JAK inhibitors Tofacitinib
(a JAK2/3 inhibitor) and JAK-inhibitor-I (a pan-JAK inhibitor)
(Supplementary Figure 2). MARIMO cells were more resistant to
both inhibitors than seven cell lines harboring mutant
JAK2 or JAK3. Dose response studies using the clinically
approved JAK-inhibitor Ruxolitinib (INCB018424, a JAK1/2
inhibitor) showed that HEL and UKE-1 (both JAK2V617F positive)
had IC50 values of 217 and 430 nM, respectively (Figure 2c).
In marked contrast the IC50 value for MARIMO was greater than
10 000 nM, demonstrating that MARIMO was not dependent on
JAK2 signaling. Consistent with these data, western blot analysis
showed that, compared with JAK2-mutant cells, MARIMO cells
contained markedly reduced levels of JAK2, phosphorylated-
JAK2 (pJAK2), STAT5 and pSTAT5 (Figure 2d). The lack of JAK2-
STAT5 signaling was not accompanied by a compensatory
increase in STAT1 or STAT3 phosphorylation (Figure 2e). JAK2
transcript levels in MARIMO were similar to other cell lines
(Figure 2f), suggesting either decreased translation or increased
degradation of JAK2.
Together, our data demonstrate that the MARIMO cell line
harbors a CALR mutation and yet is not dependent on JAK/STAT
signaling, in marked contrast to JAK2-mutated cell lines.
Our results therefore raise the possibility that mutations of
CALR and JAK2 may share activation of pathways other than the
STATs. Superﬁcially our data appear to contrast with reports that
JAK2-unmutated and CALR-mutated MF patients respond to
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ruxolitinib.14,15 However in JAK2V617F-positive patients studies
of mutant allele burden show that Ruxolitinib has a minimal
effect on the mutant clone.15 It is therefore likely that the clinical
responses to Ruxolitinib (reduced splenomegaly and improved
constitutional symptoms) do not reﬂect a cytotoxic effect
of the drug on the neoplastic clone, but instead are at least in
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Figure 1. Identiﬁcation of a CALR-mutated human cell line. (a) Top panel shows the mutated region in CALR exon 9 (red bases). The
commonest CALR mutations are shown above the DNA sequence. Solid gray line shows type 1 (52- bp deletion; c.1099_1150del; L367fs*46)
and gray arrow shows type 2 (5- bp insertion; c.1154_1155_ins; K385fs*47 mutations). The CALRmutation in human cell line MARIMO is shown
below the DNA sequence. Solid red line and capillary sequencing image show a heterozygous 61-bp deletion (c.1099_1159del; L367fs*43) in
MARIMO. Dashed gray and red lines represent the homologous sequence ﬂanking the deleted regions in type 1 and MARIMO mutations,
respectively, also highlighted in the capillary sequencing image (pale blue) for MARIMO. Lower panel shows the predicted protein sequence
of the commonest CALR mutations and of MARIMO with total protein sizes. Amino acids (AA) in the new reading frame are shaded blue and
the common novel peptide sequence shared by the different CALR variants are in bold blue. (b) PCR ampliﬁcation of CALR exon 9 followed by
fragment size analysis, as used for diagnostic testing for CALR mutations. Vertical heights of peaks represent dye signal intensity and
horizontal position of peaks reﬂect the fragment size of the PCR amplicon. Wild type (wt) peak occurs at 132- bp. Left panel shows wt and
mutated alleles of MARIMO (61-bp separation in peaks), middle panel shows Type 1/L367fs*46 with peak separation of 52 bp and right panel
shows Type 2/K385fs*47 peaks separated by 5 bp. (c) Agarose gel image showing wt (upper band) and mutated-CALR (lower band) in
MARIMO DNA and cDNA. (d) Quantitative real-time PCR of total CALRmRNA levels expressed as a fold change relative to house-keeping RPLP0
levels, for the cell lines MARIMO, the BCR-ABL1+ CML cell line K562, and the JAK2V617F+ cell lines HEL, UKE-1 and SET-2. Graph depicts all data
points generated in two independent experiments performed in duplicate. ***Po0.001 (e) Western blot showing total CALR protein levels of
MARIMO and four other myeloid cell lines.
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part due to down-modulation of pro-inﬂammatory signaling
cascades.16
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Figure 2. Characterization of the cell line MARIMO. (a and b) Basal cytoplasmic calcium level (a) and changes in cytoplasmic calcium levels
over time upon addition of thapsigargin (b) in MARIMO and ﬁve other leukemic cell lines. (c) Dose response curves for the JAK2-inhibitor
Ruxolitinib in the cell lines MARIMO, K562, HEL and UKE-1. (d and e) Western blots showing protein levels of the inactive and phosphorylated
forms of JAK2 and STAT5 (d) and STAT1 and STAT3 (e). PC, positive control. (f) JAK2 mRNA levels expressed as fold changes relative to RPLP0 in
MARIMO and four myeloid cell lines.
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